Table 1.
Patient characteristics
| Variablea | Value |
|---|---|
| N | 59 |
| Age, years | 11 (6-13.5) |
| 2-5 years, n (%) | 13 (22) |
| 6-17 years, n (%) | 46 (78) |
| Male sex, n (%) | 33 (56) |
| Race, n (%) | |
| White | 32 (54) |
| Black | 6 (10) |
| Other | 21 (36) |
| PIM2 risk of mortality | 3.7 (1.3-4.8) |
| PRISM III score | 11 (8-16) |
| Source of infection, n (%) | |
| Primary bacteremia | 6 (10) |
| Respiratory | 27 (46) |
| Abdominal | 7 (12) |
| Genitourinary | 6 (10) |
| Other | 13 (22) |
| Bacterial or fungal pathogen | 30 (51) |
| ≥ 3 comorbid conditions, n (%) | 37 (63) |
| Cancer, n (%) | 12 (20) |
| Active chemotherapy and leukopenia, n (%) | 9 (15) |
| Lymphopenia on study day 0-2, n (%) | 32 (54) |
| Corticosteroidsb, n (%) | 39 (66) |
| Hydrocortisone | 25 (42) |
| Dexamethasone | 7 (12) |
| Methylprednisolone | 11 (19) |
| Immunomodulator therapyb,c, n (%) | 7 (12) |
| Immunoglobulinb, n (%) | 4 (7) |
| Blood product transfusionb, n (%) | 28 (47) |
| PRBC | 24 (41) |
| Platelet | 15 (25) |
| FFP | 11 (19) |
| Cryoprecipitate | 2 (3) |
| 28-day mortality, n (%) | 3 (5) |
PIM2, pediatric index of mortality-2; PRISM, pediatric risk of mortality; PRBC, packed red blood cell; FFP, fresh frozen plasma
a
Medians with interquartile range reported unless otherwise specified
b
Therapies administered at any point during study day 0-7
c
canakinumab, anakinra, tocilizumab, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor